F. Pinto
and moving beyond the “obvious”
to implementation through clinical cases
to implementation through clinical cases
Speakers
Prof. Pedro Schwartzmann
(Brazil)
Prof Jose Antonio Magaña Serrano
(Mexico)
Prof. Pedro Schwartzmann
(Brazil)
Prof Jose Antonio Magaña Serrano
(Mexico)
Organized by
Supported by an educational
grant provided by
when and how to intervene?
Monday, June 12th 2023
1:00 pm CEST
Speakers
D.Capodanno
Courage, Orbita, Ischemia and REVIVED-BCIS2:
what have we learned from trials and what do we apply in clinical practice?
L. Gowdak
Treating angina where it hurts: when optimal medical treatment is adapted to the cause
when and how to intervene?
Monday, June 12th 2023
1:00 pm CEST
Speakers
D.Capodanno
Courage, Orbita, Ischemia and REVIVED-BCIS2:
what have we learned from trials and what do we apply in clinical practice?
L. Gowdak
Treating angina where it hurts: when optimal medical treatment is adapted to the cause
when and how to intervene?
Monday, June 12th 2023
1:00 pm CEST
Speakers
D.Capodanno
Courage, Orbita, Ischemia and REVIVED-BCIS2:
what have we learned from trials and what do we apply in clinical practice?
L. Gowdak
Treating angina where it hurts: when optimal medical treatment is adapted to the cause
8 December 2021
by Z. Beketova 6 February 2023Currently, the management of stable coronary artery disease is based upon the idea of flow-limiting atherosclerotic obstructions. Hence, revascularisation has been a focus due to obstructions being viewed as the cause of angina and myocardial ischemia. However, many randomised controlled trials (RCTs) have proven that revascularisation does not reduce mortality…..
Latest featured publications
by Z. Beketova 6 February 2023by Z. Beketova 6 February 2023by Z. Beketova 2 February 2023by Z. Beketova 2 February 2023by Z. Beketova 25 January 2023Latest Videos
1 September 2022HF management in real-world clinical practice (s.2-p.7)
1 September 2022HF management in real-world clinical practice (s.2-p.6)
1 September 2022HF management in real-world clinical practice (s.2-p.5)
1 September 2022HF management in real-world clinical practice (s.2-p.4)
1 September 2022HF management in real-world clinical practice (s.2 –…
1 September 2022HF management in real-world clinical practice (s.2 –…
upcoming Webinar
Latest pubmed articles
- A teenage boy with acute myocarditis and reversible microvascular angina: A case report
- Predictive value of the systemic immune inflammatory index in cardiac syndrome x
- Initial single-center experience of a standardized protocol for invasive assessment of ischemia and non-obstructive coronary artery disease
- Longitudinal Strain Analysis and Correlation with TIMI Frame Count in Patients with Ischemia with No Obstructive Coronary Artery (INOCA) and Microvascular Angina (MVA)
- HbA1c is related to microcirculation blood perfusion in patients with coronary microvascular disease using stress perfusion cardiac magnetic resonance: An observational study
- Effect of Proprietary Chinese Medicine on Coronary Microvascular Dysfunction in Patients with Microvascular Angina: A Systematic Review and Meta-Analysis
- Angina Pectoris and the Importance of Coronary Microcirculation in Practice
- Reassured on a background of vulnerability - people with microvascular angina 12 months after high-intensity physical exercise program
- Updates on Pharmacologic Management of Microvascular Angina
- Beyond Coronary Artery Disease: Assessing the Microcirculation
- Prognostic association of plasma NT-proBNP levels in patients with microvascular angina -A report from the international cohort study by COVADIS
- Exploring the mechanism of Shexiang Tongxin dropping pill in the treatment of microvascular angina through network pharmacology and molecular docking
- Refractory microvascular angina in hypertrophic cardiomyopathy: a novel therapy?
- Phenotype-based management of coronary microvascular dysfunction
- Definition and epidemiology of coronary microvascular disease